BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 21, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BF-200 ALA: Additional Phase III data

Additional data from a placebo-controlled, German Phase III trial in 112 patients with 4-8 keratoses showed that in patients treated with BF-200 ALA in combination with Aktilight CL 128, 11/164 (6.7%) keratoses...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >